Our Mission
SperoSeq is dedicated to the principle that clinical trial access should be an equitable right, not a logistical hurdle. Our mission is to accelerate patient access and clinical research by unifying the fragmented global clinical trial landscape into one powerful, high-fidelity platform.
By utilizing advanced matching algorithms, we bridge the critical gap between patients and cutting-edge research, tailored specifically to unique genetic biomarkers and clinical profiles. SperoSeq puts the power directly in patients’ hands—enabling fast, independent trial discovery that bypasses traditional institutional bottlenecks.
Simultaneously, we serve the broader scientific community by delivering actionable, de-identified insights to researchers, administrators, and developers. By streamlining the path from diagnosis to enrollment, we aim to foster an ecosystem where life-saving oncology trials are more visible, accessible, and efficient for everyone involved.
Methodology
Precision Algorithmic Pipeline
SperoSeq employs a multi-layered computational approach to solve the "needle in the haystack" problem of oncology trials. Our methodology moves beyond basic keyword matching to understand the biological context of a patient's condition.
1. Structural Data Normalization
Clinical trial registries often contain non-normalized, unstructured text. SperoSeq parses these registries to extract rigorous inclusion and exclusion parameters, converting qualitative descriptions into quantitative data points ready for comparison.
2. Genomic & Biomarker Correlation
Our engine prioritizes "high-fidelity" matches by cross-referencing patient histology and genetic sequencing (e.g., NGS reports) with trial-specific molecular targets. This ensures that patients are only seeing trials where their specific genomic profile is a primary focus of the study.
3. Probabilistic Eligibility Scoring
By applying probabilistic logic to trial criteria, we rank opportunities based on the statistical likelihood of enrollment success. This accounts for complex variables such as prior lines of therapy, current ECOG performance status, and geographic proximity to trial sites.
4. Distributed Registry Polling
The clinical landscape changes daily. Our architecture utilizes distributed workers to continuously poll global registries, ensuring that when a trial closes or a new site opens, SperoSeq reflects that change in near real-time.
Terms of Service
By accessing SperoSeq, you agree to the following legally binding terms governing research facilitation and platform usage:
1. Scope of Service & Medical Disclaimer
- Non-Clinical Entity: SperoSeq is a technology provider, not a medical practitioner. We do not provide clinical diagnoses or treatment plans.
- Professional Consultation: All matching data is for informational purposes. Users must consult with a board-certified oncologist before acting on any trial information.
- No Doctor-Patient Relationship: Use of this platform does not establish a provider-patient relationship between you and SperoSeq.
2. Data Integrity & User Responsibility
- Verification Requirement: While we aggregate data from global registries, SperoSeq does not warrant that trial status, locations, or criteria are exhaustive or real-time.
- Accuracy of Submission: Users are responsible for the clinical accuracy of the genetic biomarkers and histology reports they upload. Incorrect data will lead to invalid matching.
- Platform Limitations: SperoSeq is not liable for the failure of a user to be accepted into a trial or for the results of any trial participated in.
3. Intellectual Property & Indemnity
- Proprietary Algorithms: The SperoSeq matching engine and scoring logic are the exclusive intellectual property of SperoSeq.
- Limited License: Users are granted a non-transferable license to access the platform for personal or authorized clinical research use only.
- Indemnification: You agree to indemnify SperoSeq against any claims arising from misuse of data or reliance on matching results as a primary medical diagnostic.
Privacy Policy
SperoSeq employs a "Privacy by Design" architecture to ensure patient confidentiality through rigorous safeguards:
Encryption and Data Custody
- Advanced Encryption: All data is secured using AES-256-GCM encryption at rest. For data in motion, we mandate TLS 1.3 with Perfect Forward Secrecy (PFS).
- Database Isolation: We utilize a multi-tenant isolation strategy where PII and PHI are stored in logically separated cryptographic envelopes.
- Key Management: Cryptographic keys are rotated frequently and managed via HSMs ensuring no single entity can access decrypted data.
Access Control and Governance
- Zero-Knowledge Principles: Administrative access to raw clinical data is strictly prohibited. Internal tools operate on a "blinded" basis.
- Audit Logging: Every interaction with our database is logged in an immutable, append-only ledger monitored for anomalous behavior.
- Right to Erasure: Users may request permanent deletion of clinical profiles, resulting in the data being cryptographically shredded.
Data Sharing & Research Authorization
HIPAA Safe Harbor Compliance & De-identification
By executing this waiver, you provide express authorization for SperoSeq to create a de-identified dataset in accordance with 45 CFR § 164.514(b)(2).
Our process utilizes statistical k-anonymity to ensure the risk of re-identification is negligible. We remove the following 18 identifiers:
Institutional Research and Licensing
- Quantifying unmet medical needs in genomic subpopulations.
- Informing Phase I-III clinical trial protocol designs.
- Accelerating targeted therapy development for rare markers.
Licensees are strictly prohibited from attempting to re-identify any data subjects.
API Disclosure & Transmission
To facilitate real-time trial matching, SperoSeq transmits pseudonymized clinical attributes to external oncology databases.
Technical Transmission Protocol
- Payload Minimization: Only minimum necessary clinical tokens (Stage, Mutation, etc.) are transmitted.
- Authentication: Transmissions are secured via short-lived JWTs and Mutual TLS (mTLS).
- Whitelisting: SperoSeq only communicates with vetted, HIPAA or SOC2 compliant registries.
Security Statement: No PII—including names or government identifiers—is ever exposed to external API endpoints.
API Access
Integrate SperoSeq Intelligence into your existing clinical workflows.
We provide robust, secure API endpoints for institutional partners, healthcare systems, and research organizations looking to automate oncology trial matching and data retrieval. Our API is designed with high availability and strict HIPAA compliance to ensure seamless integration with your EHR or research platform.
To request an API key or view our technical documentation, please contact our developer relations team.
Frequently Asked Questions
Is SperoSeq free for patients?
Yes. Our core mission is to remove barriers to trial entry. SperoSeq is free for individual patients seeking trial matches for their own clinical care.
How current is the clinical trial data?
We utilize distributed registry polling to monitor global trial databases. Our matching engine reflects updates in near real-time, typically within 24 hours of a registry change.
Can SperoSeq guarantee trial enrollment?
No. SperoSeq provides a high-fidelity match based on your clinical data, but final enrollment eligibility is always determined by the specific trial’s principal investigator and clinical site.
Does SperoSeq sell my personal health information?
We never sell PII (Personally Identifiable Information). We only license de-identified, aggregated datasets to research institutions to improve subpopulation oncology research, as outlined in our Data Sharing section.
Contact Us
Have questions regarding your data, technical issues, or institutional partnerships?
SperoSeq is committed to providing a seamless experience for patients and researchers alike. To ensure you receive the most relevant and precise assistance, our team personally manages every support request. We will follow up with you as soon as we have reviewed your case.